Oncomine Content CenterGet the latest updates and learn how others are using Oncomine Solutions to further precision oncology

Detect both known and novel NTRK gene fusions using a single Oncomine assay

NTRK gene fusions can drive unregulated cell growth and proliferation in a range of cancer types. Recently, these fusions have gained significant focus and attention in precision oncology clinical research.

Next-Generation Sequencing provides the most comprehensive view across a large number of genes and can identify NTRK gene fusions as well as other actionable alterations, with minimal sample tissue needed.

Download our educational guide

Featured Videosre

Watch some of our most recent videos. Be sure to check back or subscribe for updates.

Assess a range of variants for myeloid malignancies using a single assay
How Maddie overcame childhood cancer thanks to precision oncology
Diagnosing and treating pediatric cancers with Dr. Timothy Triche

Publications, articles, and white papers

Read Dr. Timothy Triche’s perspective on precision medicine and the multi-dimensional challenges associated with cancer.
Learn how an NGS liquid biopsy assay can detect primary tumor drivers and resistance mutations using cell-free total nucleic acid
Learn how Dr. Timothy Triche of Children’s Hospital of Los Angeles is using genomic data to inform treatment decisions for pediatric cancer.
Read about the importance of low tissue requirements for improving oncology biomarker testing for pathologists, clinicians and patients. Dr. David Moore discusses his experience and the results of a three-year NSCLC molecular testing audit.
Read how analytical verification of the Oncomine Lung cfDNA Assay shows accurate measurement of low-frequency variants in cell-free DNA.
Read about the advantages of NGS liquid biopsies and why they are becoming the laboratory professionals’ assay of choice.

Recent Webinars

Endeavor to leave no patient behind: NGS in routine NSCLC biomarker testing

This CAP TODAY webinar explains how to make NSCLC biomarker testing a routine part of your care process.

Using the Cancer Genetics Inc. (CGI) testing model and case studies, you'll discover how to practice precision oncology in a way that ensures even challenging samples get tested, so you can achieve the best outcome for as many patients as possible.

If you have any questions after the webinar, be sure to get in touch with our NGS consultants and we'll be happy to provide the answers you need.

Ask an expert

Determining tumor mutation load using Oncomine Tumor Mutation Load Research Assay

Watch this on-demand webinar to learn how the Oncomine Tumor Mutation Load Assay can be used in a pathology laboratory to determine tumor mutation burden, an emerging biomarker, even when you have limited FFPE material.

New frontiers in liquid biopsy webinar series

Experience a three-part webinar series that will explore the successful implementation of NGS liquid biopsy assays across different tumor types.

Part 1: Dr. Bellosillo discusses the impact of CNV and fusion content for clinical research
Part 2: How a liquid biopsy pan-cancer assay addresses two unmet needs
Part 3: NGS liquid biopsy assay enables quantitative analysis in metastatic breast cancer research

European experts share their experience with implementing Tumor Mutation Burden testing

Dr. Nicola Normanno explains why standardization is important for the TMB biomaker
Dr. Wolfram Jochum shares his experience using the Oncomine Tumor Mutation Load Assay in his study
Dr. Paul Hofman compares Oncomine Tumor Mutation Load Assay with the FoundationOne test

Featured Infographic

See how low sample input requirements with Oncomine Dx Target Test enables more patients to be successfully tested.

Download the infographic

Thermo Fisher Scientific and its affiliates are not endorsing, recommending, or promoting any use or application of Thermo Fisher Scientific products presented by third parties during this seminar. Information and materials presented or provided by third parties are provided as-is and without warranty of any kind, including regarding intellectual property rights and reported results. Parties presenting images, text and material represent they have the rights to do so.